Asclepix Therapeutics, Inc. AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME) January 5, 2021
Read More
Read news items items specific to Ponce Therapeutics or about other Rapha Capital-related entities. Also see scientific articles detailing the rapid advances in the important science of anti-aging
News
NexImmune Inc. NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor Zeldis formerly served as Celgene CMO and CEO of Celgene…
NexImmune Inc. Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition Initial data demonstrate early signs of safety, tolerability and…
Poseida Therapeutics and Rapha Capital Management Rapha Capital Management Participates in Series D Financing for Poseida Therapeutics June 25, 2020
Asclepix Therapeutics, Inc. Better than Eylea, as durable as gene therapy? Perceptive, Xontogeny boost ophthalmic startup’s shot for best of all worlds Amber Tong, Editor, ENDPOINTS NEWS June 24, 2020
Asclepix Therapeutics, Inc. AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis Frank Vinluan, Editor, Xconomy June 24, 2020